Skip to main content
. Author manuscript; available in PMC: 2021 Jun 1.
Published in final edited form as: Cancer. 2017 Sep 28;124(2):306–314. doi: 10.1002/cncr.31038

Figure 5.

Figure 5.

(A) In contrast to other studied FLT3 inhibitors, CZT has significantly more potent activity against the Ba/F3 internal tandem duplication/F691L-mutant cell line under both medium and plasma conditions. (B) Cabozantinib potently suppressed FLT3/F691L in samples assessed with the plasma inhibitory assay. CZT indicates cabozantinib; FLT3, FMS-like tyrosine kinase 3; IC50, half-maximal inhibitory concentration; pFLT3, phosphorylated FMS-like tyrosine kinase 3.